Diabetes Oral Medications/Anti-Diabetic Medications

Drugs used in diabetes treat diabetes mellitus by lowering glucose levels in the blood. With the exceptions of Insulin, exenatide, liraglutide and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of anti-diabetic drugs, and their selection depends on the nature of the diabetes, age and situation of the person, as well as other factors.
Diabetes mellitus type 1 is a disease caused by the lack of insulin. Insulin must be used in Type I, which must be injected.
Diabetes mellitus type 2 is a disease of insulin resistance by cells. Type 2 diabetes mellitus is the most common type of diabetes. Treatments include (1) agents that increase the amount of insulin secreted by the pancreas, (2) agents that increase the sensitivity of target organs to insulin, and (3) agents that decrease the rate at which glucose is absorbed from the gastrointestinal tract.
Several groups of drugs, mostly given by mouth, are effective in Type II, often in combination. The therapeutic combination in Type II may include insulin, not necessarily because oral agents have failed completely, but in search of a desired combination of effects. The great advantage of injected insulin in Type II is that a well-educated patient can adjust the dose, or even take additional doses, when blood glucose levels measured by the patient, usually with a simple meter, as needed by the measured amount of sugar in the blood.

Insulin sensitizers address the core problem in Type II diabetes—insulin resistance.

Thiazolidinediones (TZDs), also known as "glitazones," bind to PPARγ, a type of nuclear regulatory protein involved in transcription of genes regulating glucose and fat metabolism.
Secretagogues are drugs that increase insulin output from the pancreas. Meglitinides help the pancreas produce insulin and are often called "short-acting secretagogues".
Alpha-glucosidase inhibitors are "diabetes pills" but not technically hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. Dipeptidyl peptidase-4 (DPP-4) inhibitors increase blood concentration of the incretin GLP-1 by inhibiting its degradation by dipeptidyl peptidase-4. Glycosurics are SGLT-2 inhibitors block the re-uptake of glucose in the renal tubules, promoting loss of glucose in the urine.

  • Meglitinides – nateglinide (Nonsulfonylurea secretagogues)
  • Biguanides – metformin (Insulin Sensitizers)
  • Sulfonylureas - glimepiride, glipizide, glyburide ( Secretagogues)
  • Thiazolidinediones (Tzd) – pioglitazone (Insulin Sensitizers)
  • Alpha-glucosidase inhibitors – Acarbose (Diabetes Pills)
  • Injectable Incretin mimetics
  • Injectable Amylin analogues
  • Glycosurics (sodium/glucose cotransporter 2 (SGLT2)Inhibitors)

Related Conference of Diabetes Oral Medications/Anti-Diabetic Medications

May 17-18, 2019

2nd Global Experts Meeting on Diabetes, Hypertension & Metabolic Syndrome

Holiday Inn Singapore Atrium | Singapore
May 30-31, 2019

2nd Global Meeting on Diabetes and Endocrinology

Istanbul, Turkey
July 29-30, 2019

21st Asia Pacific Diabetes Conference

Sydney, Australia
June 27-28, 2019 |

18th Global Conference on Diabetes and Nursing Care

Amsterdam, Netherlands
July 17-18, 2019

28th European Diabetes Congress

| Edinburgh, Scotland
July 24-25, 2019

29th World Diabetes & Heart Congress

Melbourne, Australia
September 18-19, 2019

12th International Conference on Diabetes & Metabolism

San Francisco | California | USA
September 21-22, 2019

15th World Congress on Endocrinology & Diabetes

| Prague, Czech Republic
September 21-22, 2019

Euro Diabetes Congress & Expo

Prague, Czech Republic
October 14-15, 2019

Global congress on Endocrinology and Gynecology

Sydney, Australia
October 23-24, 2019

Annual Summit on Metabolomics

Amsterdam, Netherlands
November 25-26, 2019

Global Summit On Diabetes & Endocrinology

Yokohama, Japan
December 02-03, 2019 |

14th European Diabetes and Endocrinology Congress

Barcelona, Spain
December 04-05, 2019

3rd Annual Congress on Diabetes and Its Complications

Tokyo, Japan

Diabetes Oral Medications/Anti-Diabetic Medications Conference Speakers

Recommended Sessions

Related Journals

Are you interested in